Soft chewable dosage form

US12083218B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12083218-B2
Application numberUS-202117447453-A
CountryUS
Kind codeB2
Filing dateSep 13, 2021
Priority dateOct 18, 2018
Publication dateSep 10, 2024
Grant dateSep 10, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the soft chewable dosage form.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for treating a subject suffering from a disease or disorder in the gastro intestinal tract comprising administering a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material/matrix comprising a first lipid and a second lipid, wherein the second lipid is a plasticizer, wherein the lipid encapsulated active pharmaceutical ingredient is embedded in the soft chewable dosage form, and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient. 2. A method according to claim 1 , wherein the disease or disorder in the gastro intestinal tract is peptic ulcers, gastric ulcers, hyperacidity, gastroesophageal reflux disease (GERD), or gastritis. 3. A method according to claim 1 , wherein the disease or disorder in the gastro intestinal tract leads to heartburn, gas, indigestion, upper abdominal fullness, heartburn, nausea, belching, upper abdominal pain, or feeling full earlier than expected when eating.

Assignees

Inventors

Classifications

  • 1,3-Thiazoles · CPC title

  • Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title

  • Flavour masking or reducing agents · CPC title

  • containing sugars or derivatives · CPC title

  • using additives (addition of substantially indigestible substances A23L33/21) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12083218B2 cover?
The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tr…
Who is the assignee on this patent?
Johnson & Johnson Consumer Inc
What technology area does this patent fall under?
Primary CPC classification A61K9/0056. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).